BMO Capital Maintains Outlook On ICON Public Limited Company (ICLR) After Management Call

ICON Public Limited Company (NASDAQ:ICLR) is among the cheap healthcare stocks to buy heading into 2026. On December 4, BMO Capital maintained its ‘Market Perform’ rating and $175 price target on ICON Public Limited Company (NASDAQ:ICLR) after the analyst call with management. During the call, many topics were discussed, including senior executive change and ongoing trends surrounding cancellations.

The analyst also assessed the company’s dynamics in functional work relative to its full-service offerings, along with its plans to increase investments in automation and agentic AI. Additionally, the call discussed the higher pass-through revenue and how it could influence margins in the times ahead, the analyst stated.

Laboratory, Medicine, Health

Photo by Akram Huseyn on Unsplash

According to TheFly, BMO Capital started its coverage on ICON Public Limited Company (NASDAQ:ICLR) on November 13, with a ‘Market Perform’ rating and $175 price target. In that update, the analyst noted that the company’s cancellations will remain elevated in the upcoming quarters. The analyst further added that the company is probably through the worst period now.

Overall, ICON Public Limited Company (NASDAQ:ICLR) has a ‘Buy’ or equivalent rating from most of the analysts covering the stock. With a one-year median price target of $213.50, the stock has an upside potential of nearly 15%.

ICON Public Limited Company (NASDAQ:ICLR) is an Ireland-based clinical research organization that offers outsourced development and commercialization services. Founded in 1989, the company is committed to delivering leading clinical research solutions.

While we acknowledge the potential of ICLR to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ICLR and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.